Kazuya Sakai

Kashihara, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 66 publications

Clinical implications of ADAMTS13 conformation ELISA in immune-mediated TTP with undetectable ADAMTS13 antigen.

Clinical implications of ADAMTS13 conformation ELISA in immune-mediated TTP with undetectable ADAMTS13 antigen.

Journal: Journal of thrombosis and haemostasis : JTH

Published: June 25, 2026

Dynamic gap structure for high-throughput measurement of cellular mechanical properties.

Dynamic gap structure for high-throughput measurement of cellular mechanical properties.

Journal: Lab on a chip

Published: May 01, 2026

Vasoproliferative Retinal Tumor with Hemangioblastoma-like Features: Evaluation with von Wilebrand Factor.

Vasoproliferative Retinal Tumor with Hemangioblastoma-like Features: Evaluation with von Wilebrand Factor.

Journal: Journal of clinical medicine

Published: April 14, 2026

Haemoglobin vesicles as artificial red blood cells developed for use as a transfusion alternative: an open-label, single-centre phase Ib study protocol in Japan.

Haemoglobin vesicles as artificial red blood cells developed for use as a transfusion alternative: an open-label, single-centre phase Ib study protocol in Japan.

Journal: BMJ open

Published: January 22, 2026

Alloantibody to Recombinant ADAMTS13 Reduces Clinical Efficacy in Congenital TTP: An Emerging Therapeutic Concern.

Alloantibody to Recombinant ADAMTS13 Reduces Clinical Efficacy in Congenital TTP: An Emerging Therapeutic Concern.

Journal: American journal of hematology

Published: November 10, 2025

Impact of haemoglobin vesicles on pretransfusion testing and mitigation strategies.

Impact of haemoglobin vesicles on pretransfusion testing and mitigation strategies.

Journal: Vox sanguinis

Published: August 20, 2025

Recurrent Thrombocytopenia During Caplacizumab Therapy in Acute Immune-Mediated Thrombotic Thrombocytopenic Purpura.

Recurrent Thrombocytopenia During Caplacizumab Therapy in Acute Immune-Mediated Thrombotic Thrombocytopenic Purpura.

Journal: American journal of hematology

Published: July 24, 2025

Plasma exchange-free therapeutic management of immune-mediated thrombotic thrombocytopenic purpura

Plasma exchange-free therapeutic management of immune-mediated thrombotic thrombocytopenic purpura

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: July 06, 2025

Validation of plasmin-cleaved VWF as a biomarker for microthrombosis in Japanese patients with acute immune-mediated TTP.

Validation of plasmin-cleaved VWF as a biomarker for microthrombosis in Japanese patients with acute immune-mediated TTP.

Journal: Blood vessels, thrombosis & hemostasis

Published: June 18, 2025

Prognostic relevance of early clinical and laboratory findings in immune-mediated thrombotic thrombocytopenic purpura.

Prognostic relevance of early clinical and laboratory findings in immune-mediated thrombotic thrombocytopenic purpura.

Journal: Research and practice in thrombosis and haemostasis

Published: March 27, 2025

Challenges in managing iTTP: insights into ADAMTS13 inhibitor boosting during caplacizumab therapy.

Challenges in managing iTTP: insights into ADAMTS13 inhibitor boosting during caplacizumab therapy.

Journal: Annals of hematology

Published: February 12, 2025

Therapeutic switch from plasma to recombinant ADAMTS13 for patients with congenital TTP from Japanese real-world data.

Therapeutic switch from plasma to recombinant ADAMTS13 for patients with congenital TTP from Japanese real-world data.

Journal: Blood

Published: November 08, 2024

Showing 1-12 of 66

Last Updated: 09/26/2026